1. Курилович С.А., Чекалина Е.А., Белковец А.В., Щербакова Л.В. Дозозависимая антисекреторная активность эзомепразола: результаты длительного мониторирования внутрижелудочного рН. Рос. журн. гастроэнтерол. гепатол. колопроктол. 2016; 26(3):33-40.

2. Платошкин Э.Н. // Мед. новости. - 2007. - №10. - С. 25-30.

3. Chao-Hung K., Chien-Yu Lu., Hsiang-Yao Shih, Chung-Jung L. et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20(43): 16029-36.

4. Kahrilas P.J., Falk G.W., Johnson D.A. et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14(10):1249-58.

5. Lind T., Kyleback A., Rydberg L. et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.

6. Olbe L., Carlsson E., Lindberg P.A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Dis 2003; 2:132-9

7. Rodrigues A.D., Rushmore T.H. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr Drug Metab 2002; 3:-P. 289-309.

8. Teng M., Khoo A.L., Zhao Y.J. et al. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. J Clin Pharm Ther 2015; 40(4):368-75

9. Vakil N., van Zanten S., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus // Am. J. Gastroenterol. - 2006. - 101. - P.1900-1920.